SCHEMBL23964262

SCHEMBL23964262

COc1cncnc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.54
TLR9 Q9NR96 3/20 0.49
KIT P10721 2/20 0.49
TLR7 Q9NYK1 2/20 0.46
CKS1B P61024 1/20 0.46
SKP1 P63208 1/20 0.46
SKP2 Q13309 1/20 0.46
GBA1 P04062 1/20 0.44
MAP4K4 O95819 1/20 0.44
ACHE P22303 1/20 0.44
BACE1 P56817 1/20 0.44
ALK Q9UM73 2/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040718 1.00 GPR119 (0.54) GPR119TLR9KITTLR7CKS1B
SCHEMBL26669585 0.86 GPR119 (0.48) GPR119KITCKS1BSKP1SKP2
SCHEMBL10319563 0.85 GPR119 (0.53) GPR119KITCKS1BSKP1SKP2
SCHEMBL2798741 0.85 KIT (0.51) GPR119TLR9KITCKS1BSKP1
SCHEMBL2422161 0.84 KIT (0.50) GPR119KITCKS1BSKP1SKP2
SCHEMBL2796054 0.84 KIT (0.53) GPR119KITCKS1BSKP1SKP2
SCHEMBL25506032 0.84 KIT (0.50) GPR119KITCKS1BSKP1SKP2
SCHEMBL30417388 0.84 KIT (0.50) GPR119KITCKS1BSKP1SKP2
SCHEMBL2796899 0.84 KIT (0.50) GPR119KITCKS1BSKP1SKP2
SCHEMBL25180617 0.83 ACHE (0.48) KITACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 GPR119 2957/4885TLR9 1303/4885KIT 4871/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 GPR119 136/4885TLR9 3842/4885KIT 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.